By John Foley and Neil Unmack
LONDON (Reuters Breakingviews) - Painkillers and pile cream: these are either the recipe for a terrible night in, or a potentially good corporate deal. Pfizer, the $215 billion U.S. drugmaker, has tasked investment banks with looking into a spinoff or sale of its consumer-goods division, which makes Advil and Preparation H. New GlaxoSmithKline boss Emma Walmsley would be well placed to offer a home.
Over-the-counter products are a tiny sideline for Pfizer, accounting for just 6.4 percent of its revenue last year. Pfizer Chief Executive Ian Read therefore loses little from putting the business on the block. While these goods might share manufacturing and shipping processes with prescription medicines, the unique nature of cooking up, testing and distributing drugs to patients suggests there’s not much reason to keep them together. Germany’s Merck is considering a similar split.
Of course, some are less dismissive – including Walmsley. She took over as CEO in April, having run the consumer-goods joint venture Glaxo co-owns with Switzerland’s Novartis. Walmsley has pledged to focus on Glaxo’s drugs, like its HIV and asthma meds, rather than her old division, which makes just 15 percent of group operating profit. But as she will know, consumer goods are a game of scale – something rivals like Sanofi, Reckitt Benckiser and Johnson & Johnson also covet.
A neat solution would be to fold Pfizer’s consumer business into the Glaxo-Novartis joint venture. Valued at 15 times operating profit – roughly the 10-year average for the consumer-staples sector – the business could be worth $10 billion. That assumes Pfizer’s consumer operating margin is roughly the same 20 percent that Glaxo is targeting. Since Glaxo now values its venture with Novartis at $27 billion, Pfizer could argue for a stake somewhere south of 30 percent. One day, the enlarged company might make for a more lucrative spinoff or sale than Pfizer could muster today.
Timing matters. Read says he will make a decision some time in 2018. Ideally, Glaxo would buy Novartis out before doing any other deals, since it would otherwise have to pay the Swiss for their share of any synergies that came from adding Pfizer. Besides, Walmsley has only been in the job for six months. Nonetheless, she could do worse than toss an offer over Pfizer’s counter.
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.